Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.
Broad Health Condition Metabolic and Endocrine
Specific Health ConditionNormal metabolism and endocrine development and function
Anticipated date of first participant enrolment3/08/2010
Anticipated date of last participant enrolment3/08/2010
The purpose of this study is to understand how oestrogen controls the use of fat in the liver. The hypothesis is that oestrogen is required to prevent the accumulation of fat in the liver. The mechanism may be direct or mediated by other hormones such as growth hormone, which is regulated by oestrogen. We wish to study the effects of oestrogen compounds called Selective Oestrogen Receptor Modulators (tamoxifen) and a drug that prevents oestrogen production (letrozole) on the secretion of growth hormone from the special gland in brain and how they control the liver production and burning of fat in men and women. We wish to compare these effects with that of natural oestrogen itself in women.
Key inclusion criteria
Healthy postmenopausal women and men the same age BMI <25 kg/m2
Minimum age50 Years
Maximum age70 Years
GenderBoth males and females
Key exclusion criteria
History of liver, kidney diseases, cancer, diabetes, endocrine disorders, that are likely to interfere with the metabolism or excretion of the test medication.
Sponsor Primary Sponsor Type: Other
Primary Sponsor Name: Garvan Institute of Medical Research
Primary Sponsor Address: 384 Victoria St Darlinghurst 2010 NSW
Primary Sponsor Country: Australia
Contact person for information and recruitment
Garvan Institute of Medical Research 384 Victoria St Darlinghurst 2010, NSW
+61 2 92958483
+61 2 92958481